Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Financing Activities data on file, last reported at $88.8 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 15616.78% year-over-year to $88.8 million in Q1 2026; TTM through Mar 2026 was $40.8 million, a 2642.28% increase from a year earlier, with the FY2025 full-year figure at -$48.5 million, down 120.35% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $88.8 million, up from -$2.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for LXRX reached as high as $239.4 million in Q1 2024 and fell as low as -$45.0 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $40.6 million across 5 years, with a median of -$14000.0 in 2024.
• Across the five-year window, Cash from Financing Activities soared 29151.33% in 2024 and sank 321328.57% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $24.9 million in 2022, then sank by 100.0% to -$1000.0 in 2023, then sank by 10300.0% to -$104000.0 in 2024, then tumbled by 2714.42% to -$2.9 million in 2025, then soared by 3132.32% to $88.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $88.8 million in Q1 2026, -$2.9 million in Q4 2025, and -$45.0 million in Q2 2025.